An interesting but preliminary biomarker study’s reception illustrates the challenges of conducting and communicating nuanced research in the era of social media.
Multiple clinical trial participants who have severe spinal injuries were able to stand, walk, and perform specific activities after just one day of using an implant surgically embedded in their spines.
In this webinar, Dr. Kevin Wang will discuss a precision medicine approach for treating traumatic brain injury which uses phenotype biomarkers to monitor disease course and develop novel therapies.
The Biogen-developed treatment, called lecanemab, appears to have a more clear-cut effect on slowing the disease than the company’s previous Alzheimer’s drug, Aduhelm.